Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

Journal of Pathology

Volumn 191, Issue 3, 2000, Pages 239-244

  Hobisch, Alfred ^a   Rogatsch, Hermann ^b   Hittmair, Anton ^b   Fuchs, Dietmar ^b   Bartsch Jr , Georg ^a   Klocker, Helmut ^a   Bartsch, Georg ^a   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Androgen receptor; Autocrine loop; Interleukin 6; Interleukin 6 receptor; Paracrine loop; Prostate; Prostate cancer

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ARTICLE; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ADENOCARCINOMA; AUTOCRINE COMMUNICATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-6; MALE; NEOPLASM PROTEINS; PARACRINE COMMUNICATION; PRECANCEROUS CONDITIONS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; TUMOR CELLS, CULTURED;

EID: 0033921535     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X     Document Type: Article

References (30)

1. Chung LW, Davies R. Prostate epithelial differentiation is dictated by its surrounding stroma. Mol Biol Rep 1996; 23: 13-19.
2. Degeorges A, Tatoud R, Fauvel Lafeve F, et al. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 1996; 68: 207-214.
3. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249-284.
4. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542-549.
5. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW, Characterisation of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38: 199-207.
6. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin-6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994; 151: 1396-1399.
7. Hobisch A, Eder IE, Putz T, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-4645.
8. Lin D-L, Keller ET. Mechanism of interleukin-6 promotion of androgen receptor function in prostate cancer cells. International Conference on Prostate Cancer Research, Iowa City, 1999.
9. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991; 48: 189-193.
10. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H. Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995; 55: 3068-3072.
11. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398.
12. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996; 28: 129-135.
13. Mohler JL, Chen Y, Hamil K, et al. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 1996; 2: 889-895.
14. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-128.
15. Zhang J, Hess MW, Thurnher M, et al. Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997; 30: 117-129.
16. Cronauer MV, Eder IE, Hittmair A, et al. A reliable system for the culture of human prostatic cells. In Vitro Cell Dev Biol Anim 1997; 33: 742-744.
17. Corvin S, Bosch ST, Eder IE, Thurnher M, Bartsch G, Klocker H. Video imaging of prostatic stromal-cell contraction: an in vitro model for studying drug effects. Prostate 1998; 37: 209-214.
18. Bösch ST, Corvin S, Zhang J, Rogatsch H, Bartsch G, Klocker H. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alphal-adrenergic receptor antagonist. Prostate 1999; 39: 226-233.
19. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-I. In Vitro Cell Dev Biol Anim 1995; 31: 14-24.
20. Hoosein N, Abdul M, McCabe R, et al. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in meta-static prostate cancer. Urol Oncol 1995; 1: 246-251.
21. Adler HI, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 182-187.
22. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995; 95: 2886-2895.
23. Okamoto M, Lee C, Oyasu R. Autocrine effect of androgen on proliferation of an androgcn-responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology 1997; 138: 5071-5074.
24. Qiu Y, Ravi L, Kung H-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998; 393: 83-85.
25. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138: 1145-1150.
26. Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 1998; 139: 2375-2381.
27. Mori S, Murakami-Mori K, Bonavida B. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999; 257: 609-614.
28. Basolo F, Fiore L, Fontanini G, et al. Expression and response to interleukin-6 (IL-6) in human mammary tumors. Cancer Res 1996; 56: 3118-3122.
29. Basolo F, Fiore L, Pollina L, Fontanini G, Conaldi PG, Toniolo A. Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies. Clin Cancer Res 1998; 4: 381-387.
30. Gandour-Edwards R, Kapadia SB, Gumerlock PH, Barnes L. Immunolocalization of interleukin-6 in salivary gland tumors. Hum Pathol 1995; 26: 501-503.